MTOR and hematologic disorder: To date, PTBP2, TMEM51, and MTOR have been found as fusion partners of KAZN by RNA sequencing studies in solid tumors [27, 28], while, as far as we know, rearrangements of KAZN have never been described in hematological malignancies.